References
Key articles
British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. Jul 2019 [internet publication].Full text
National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management. Mar 2021 [internet publication].Full text
Reference articles
1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2024 [internet publication].Full text
2. National Institutes of Health; National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 3: Guidelines for the diagnosis and management of asthma. Aug 2007 [internet publication].Full text
3. Weiler JM, Brannan JD, Randolph CC, et al. Exercise-induced bronchoconstriction update: 2016. J Allergy Clin Immunol. 2016 Nov;138(5):1292-5.Full text Abstract
4. GBD 2019 Diseases and Injuries Collaborators. GBD cause and risk summaries. Asthma—level 3 cause. Lancet. 2020 Oct 17;396:S109.Full text
5. Public Health England. Public health profiles: asthma. 2023 [internet publication].Full text
6. Asthma and Lung UK. What is asthma? Nov 2021 [internet publication].Full text
7. Asthma and Lung UK. What is severe asthma? Nov 2022 [internet publication].Full text
8. Centers for Disease Control and Prevention. Most recent national asthma data. May 2023 [internet publication].Full text
9. Centers for Disease Control and Prevention. Asthma as the underlying cause of death. Jul 2023 [internet publication].Full text
10. Burbank AJ, Hernandez ML, Jefferson A, et al. Environmental justice and allergic disease: a work group report of the AAAAI environmental exposure and Respiratory Health Committee and the Diversity, Equity and Inclusion Committee. J Allergy Clin Immunol. 2023 Mar;151(3):656-70.Full text Abstract
11. To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012 Mar 19;12:204.Full text Abstract
12. Singh AM, Busse WW. Asthma exacerbations. 2: aetiology. Thorax. 2006 Sep;61(9):809-16.Full text Abstract
13. Wark PA, Gibson PG. Asthma exacerbations. 3: pathogenesis. Thorax. 2006 Oct;61(10):909-15.Full text Abstract
14. Shapiro SD, Owen CA. ADAM-33 surfaces as an asthma gene. N Engl J Med. 2002 Sep 19;347(12):936-8. Abstract
15. Makoui MH, Imani D, Motallebnezhad M, et al. Vitamin D receptor gene polymorphism and susceptibility to asthma: meta-analysis based on 17 case-control studies. Ann Allergy Asthma Immunol. 2020 Jan;124(1):57-69. Abstract
16. El-Husseini ZW, Gosens R, Dekker F, et al. The genetics of asthma and the promise of genomics-guided drug target discovery. Lancet Respir Med. 2020 Oct;8(10):1045-56. Abstract
17. Ntontsi P, Photiades A, Zervas E, et al. Genetics and epigenetics in asthma. Int J Mol Sci. 2021 Feb 27;22(5):2412.Full text Abstract
18. Restori KH, Srinivasa BT, Ward BJ, et al. Neonatal immunity, respiratory virus infections, and the development of asthma. Front Immunol. 2018 Jun 4;9:1249.Full text Abstract
19. Pietinalho A, Pelkonen A, Rytilä P. Linkage between smoking and asthma. Allergy. 2009 Dec;64(12):1722-7.Full text Abstract
20. Ferreira MA, Vonk JM, Baurecht H, et al. Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. Nat Genet. 2017 Dec;49(12):1752-57. Abstract
21. Rose JJ, Krishnan-Sarin S, Exil VJ, et al. Cardiopulmonary impact of electronic cigarettes and vaping products: a scientific statement from the American Heart Association. Circulation. 2023 Aug 22;148(8):703-28.Full text Abstract
22. Joshi D, Duong M, Kirkland S, et al. Impact of electronic cigarette ever use on lung function in adults aged 45-85: a cross-sectional analysis from the Canadian Longitudinal Study on Aging. BMJ Open. 2021 Oct 27;11(10):e051519.Full text Abstract
23. Wills TA, Soneji SS, Choi K, et al. E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies. Eur Respir J. 2021 Jan;57(1):1901815.Full text Abstract
24. Orellano P, Quaranta N, Reynoso J, et al. Effect of outdoor air pollution on asthma exacerbations in children and adults: systematic review and multilevel meta-analysis. PLoS One. 2017 Mar 20;12(3):e0174050.Full text Abstract
25. Paterson CA, Sharpe RA, Taylor T, et al. Indoor PM2.5, VOCs and asthma outcomes: a systematic review in adults and their home environments. Environ Res. 2021 Nov;202:111631.Full text Abstract
26. Nassikas NJ, McCormack MC, Ewart G, et al. Indoor air sources of outdoor air pollution: health consequences, policy, and recommendations: an official American Thoracic Society Workshop report. Ann Am Thorac Soc. 2024 Mar;21(3):365-76.Full text Abstract
27. See KC, Phua J, Lim TK. Trigger factors in asthma and chronic obstructive pulmonary disease: a single-centre cross-sectional study. Singapore Med J. 2016 Oct;57(10):561-5.Full text Abstract
28. van der Wiel E, ten Hacken NH, Postma DS, et al. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol. 2013 Mar;131(3):646-57. Abstract
29. Saikumar Jayalatha AK, Hesse L, Ketelaar ME, et al. The central role of IL-33/IL-1RL1 pathway in asthma: From pathogenesis to intervention. Pharmacol Ther. 2021 Sep;225:107847.Full text Abstract
30. Ballow M. Biologic immune modifiers: trials and tribulations - are we there yet? J Allergy Clin Immunol. 2006 Dec;118(6):1209-15. Abstract
31. Boyce JA. Asthma 2005-2006: bench to bedside. J Allergy Clin Immunol. 2006 Sep;118(3):582-6. Abstract
32. Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. J Allergy Clin Immunol. 2006 Sep;118(3):551-9. Abstract
33. Kuruvilla ME, Vanijcharoenkarn K, Shih JA, et al. Epidemiology and risk factors for asthma. Respir Med. 2019 Mar;149:16-22.Full text Abstract
34. Omland Ø, Hjort C, Pedersen OF, et al. New-onset asthma and the effect of environment and occupation among farming and nonfarming rural subjects. J Allergy Clin Immunol. 2011 Oct;128(4):761-5.Full text Abstract
35. Gabryszewski SJ, Hill DA. One march, many paths: insights into allergic march trajectories. Ann Allergy Asthma Immunol. 2021 Sep;127(3):293-300. Abstract
36. Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. Eur Respir J. 2013 Mar;41(3):716-26.Full text Abstract
37. Di Cicco M, Sepich M, Beni A, et al. How e-cigarettes and vaping can affect asthma in children and adolescents. Curr Opin Allergy Clin Immunol. 2022 Apr 1;22(2):86-94.Full text Abstract
38. Li X, Zhang Y, Zhang R, et al. Association between e-cigarettes and asthma in adolescents: a systematic review and meta-analysis. Am J Prev Med. 2022 Jun;62(6):953-60.Full text Abstract
39. Feddema JJ, Claassen E. Prevalence of viral respiratory infections amongst asthmatics: Results of a meta-regression analysis. Respir Med. 2020 Nov;173:106020.Full text Abstract
40. Laidlaw TM, Mullol J, Woessner KM, et al. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1133-41.Full text Abstract
41. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016 Mar 14;9:45-53.Full text Abstract
42. Sharma V, Cowan DC. Obesity, inflammation, and severe asthma: an update. Curr Allergy Asthma Rep. 2021 Dec 18;21(12):46.Full text Abstract
43. Miethe S, Karsonova A, Karaulov A, et al. Obesity and asthma. J Allergy Clin Immunol. 2020 Oct;146(4):685-93.Full text Abstract
44. Xu M, Lodge CJ, Lowe AJ, et al. Are adults with asthma less physically active? A systematic review and meta-analysis. J Asthma. 2021 Nov;58(11):1426-43. Abstract
45. Xu S, Gilliland FD, Conti DV. Elucidation of causal direction between asthma and obesity: a bi-directional Mendelian randomization study. Int J Epidemiol. 2019 Jun 1;48(3):899-907.Full text Abstract
46. Shore SA. Obesity and asthma: possible mechanisms. J Allergy Clin Immunol. 2008 May;121(5):1087-93. Abstract
47. King GG, Brown NJ, Diba C, et al. The effects of body weight on airway calibre. Eur Respir J. 2005 May;25(5):896-901.Full text Abstract
48. Zhu Z, Guo Y, Shi H, et al. Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK Biobank. J Allergy Clin Immunol. 2020 Feb;145(2):537-49.Full text Abstract
49. Paoletti G, Melone G, Ferri S, et al. Gastroesophageal reflux and asthma: when, how, and why. Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):52-8. Abstract
50. Cantarutti A, Barbiellini Amidei C, Valsecchi C, et al. Association of treated and untreated gastroesophageal reflux disease in the first year of life with the subsequent development of asthma. Int J Environ Res Public Health. 2021 Sep 13;18(18):9633. Abstract
51. Rogers L. Role of sleep apnea and gastroesophageal reflux in aevere asthma. Immunol Allergy Clin North Am. 2016 Aug;36(3):461-71. Abstract
52. Kopsaftis Z, Yap HS, Tin KS, et al. Pharmacological and surgical interventions for the treatment of gastro-oesophageal reflux in adults and children with asthma. Cochrane Database Syst Rev. 2021 May 17;5:CD001496.Full text Abstract
53. Prasad B, Nyenhuis SM, Imayama I, et al. Asthma and abstructive sleep apnea overlap: what has the evidence taught us? Am J Respir Crit Care Med. 2020 Jun 1;201(11):1345-57.Full text Abstract
54. Kong DL, Qin Z, Shen H, et al. Association of obstructive sleep apnea with asthma: a meta-analysis. Sci Rep. 2017 Jun 22;7(1):4088.Full text Abstract
55. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. Jul 2019 [internet publication].Full text
56. National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management. Mar 2021 [internet publication].Full text
57. Schneider A, Gindner L, Tilemann L, et al. Diagnostic accuracy of spirometry in primary care. BMC Pulm Med. 2009 Jul 10;9:31.Full text Abstract
58. Ringsberg KC, Bjärneman P, Larsson R, et al. Diagnosis of asthma in primary health care: a pilot study. J Allergy (Cairo). 2014;2014:898965.Full text Abstract
59. Melbye H, Drivenes E, Dalbak LG, et al. Asthma, chronic obstructive pulmonary disease, or both? Diagnostic labeling and spirometry in primary care patients aged 40 years or more. Int J Chron Obstruct Pulmon Dis. 2011;6:597-603.Full text Abstract
60. Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015 Nov;3(11):849-58. Abstract
61. Higgins BG, Britton JR, Chinn S, et al. The distribution of peak expiratory flow variability in a population sample. Am Rev Respir Dis. 1989 Nov;140(5):1368-72.Full text Abstract
62. Quackenboss JJ, Lebowitz MD, Krzyzanowski M. The normal range of diurnal changes in peak expiratory flow rates. Relationship to symptoms and respiratory disease. Am Rev Respir Dis. 1991 Feb;143(2):323-30.Full text Abstract
63. Higgins BG, Britton JR, Chinn S, et al. Comparison of bronchial reactivity and peak expiratory flow variability measurements for epidemiologic studies. Am Rev Respir Dis. 1992 Mar;145(3):588-93.Full text Abstract
64. Thiadens HA, De Bock GH, Dekker FW, et al. Value of measuring diurnal peak flow variability in the recognition of asthma: a study in general practice. Eur Respir J. 1998 Oct;12(4):842-7. Abstract
65. Pollart SM, Compton RM, Elward KS. Management of acute asthma exacerbations. Am Fam Physician. 2011 Jul 1;84(1):40-7.Full text Abstract
66. National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN). Nov 2024 [internet publication].Full text
67. Vandenplas O, Suojalehto H, Cullinan P. Diagnosing occupational asthma. Clin Exp Allergy. 2017 Jan;47(1):6-18.Full text Abstract
68. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30.Full text Abstract
69. Alving K, Malinovschi A. Basic aspects of exhaled nitric oxide. Exhaled biomarkers. Eur Respir Monogr. 2010;49:1-31.Full text
70. Bjermer L, Alving K, Diamant Z, et al. Current evidence and future research needs for FeNO measurement in respiratory diseases. Respir Med. 2014 Jun;108(6):830-41.Full text Abstract
71. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011 Sep 1;184(5):602-15.Full text Abstract
72. Menzies-Gow A, Mansur AH, Brightling CE. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020 Mar;55(3):1901633.Full text Abstract
73. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet. 2011 Sep 10;378(9795):983-90. Abstract
74. Honkoop PJ, Loijmans RJ, Termeer EH, et al; Asthma Control Cost-Utility Randomized Trial Evaluation (ACCURATE) Study Group. Symptom-and fraction of exhaled nitric oxide-driven strategies for asthma control: a cluster-randomized trial in primary care. J Allergy Clin Immunol. 2015 Mar;135(3):682-8. Abstract
75. Petsky HL, Kew KM, Turner C, et al. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev. 2016 Sep 1;(9):CD011440.Full text Abstract
76. Petsky HL, Li A, Chang AB. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev. 2017 Aug 24;(8):CD005603.Full text Abstract
77. Joos GF, O'Connor B, Anderson SD, et al. Indirect airway challenges. Eur Respir J. 2003 Jun;21(6):1050-68.Full text Abstract
78. Anderton RC, Cuff MT, Frith PA, et al. Bronchial responsiveness to inhaled histamine and exercise. J Allergy Clin Immunol. 1979 May;63(5):315-20.Full text Abstract
79. Wang R, Murray CS, Fowler SJ, et al. Asthma diagnosis: into the fourth dimension. Thorax. 2021 Jun;76(6):624-31.Full text Abstract
80. Boulding R, Stacey R, Niven R, et al. Dysfunctional breathing: a review of the literature and proposal for classification. Eur Respir Rev. 2016 Sep;25(141):287-94.Full text Abstract
81. Hull JH, Burns P, Carre J, et al. BTS clinical statement for the assessment and management of respiratory problems in athletic individuals. Thorax. 2022 Jun;77(6):540-51. Abstract
82. Carden KA, Boiselle PM, Waltz DA, et al. Tracheomalacia and tracheobronchomalacia in children and adults. An in-depth review. Chest. 2005 Mar;127(3):984-1005. Abstract
83. Lee KS, Sun MR, Ernst A, et al. Comparison of dynamic expiratory CT with bronchoscopy for diagnosing airway malacia: a pilot evaluation. Chest. 2007 Mar;131(3):758-64. Abstract
84. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603.Full text Abstract
85. Gatheral TL, Rushton A, Evans DJ, et al. Personalised asthma action plans for adults with asthma. Cochrane Database Syst Rev. 2017 Apr 10;(4):CD011859.Full text Abstract
86. Bruton A, Lee A, Yardley L, et al. Physiotherapy breathing retraining for asthma: a randomised controlled trial. Lancet Respir Med. 2018 Jan;6(1):19-28.Full text Abstract
87. O’Connor E, Patnode CD, Burda BU, et al. Breathing exercises and/or retraining techniques in the treatment of asthma: comparative effectiveness [internet]. (Comparative Effectiveness Reviews, No. 71.) Rockville, MD: Agency for Healthcare Research and Quality (US); Sep 2012.Full text Abstract
88. Santino TA, Chaves GS, Freitas DA, et al. Breathing exercises for adults with asthma. Cochrane Database Syst Rev. 2020 Mar 25;(3):CD001277.Full text Abstract
89. Prem V, Sahoo RC, Adhikari P. Comparison of the effects of Buteyko and pranayama breathing techniques on quality of life in patients with asthma - a randomized controlled trial. Clin Rehabil. 2013 Feb;27(2):133-41. Abstract
90. Kelly K, Spooner CH, Rowe BH. Nedocromil sodium vs. sodium cromoglycate for preventing exercise-induced bronchoconstriction in asthmatics. Cochrane Database Syst Rev. 2000 Jul 24;(4):CD002731.Full text Abstract
91. Nassif EG, Weinberger M, Thompson R, et al. The value of maintenance theophylline in steroid-dependent asthma. N Engl J Med. 1981 Jan 8;304(2):71-5. Abstract
92. Medicines and Healthcare products Regulatory Agency. Montelukast: reminder of the risk of neuropsychiatric reactions. Apr 2024 [internet publication].Full text
93. Clinical Effectiveness and Evaluation Unit, Pearson M, Bucknail C, eds. Measuring clinical outcome in asthma: a patient-focused approach. London: Royal College of Physicians; 1999.
94. Ahmad S, Kew KM, Normansell R. Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids. Cochrane Database Syst Rev. 2015 Jun 19;(6):CD011306.Full text Abstract
95. Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people with asthma. Cochrane Database Syst Rev. 2017 Mar 13;(3):CD012286.Full text Abstract
96. National Institute for Health and Care Excellence. Algorithm F: pharmacological treatment of chronic asthma in adults aged 17 and over. 2021 [internet publication].Full text
97. Eccles M, Rousseau N, Higgins B, et al. Evidence-based guideline on the primary care management of asthma. Fam Pract. 2001 Apr;18(2):223-9.Full text Abstract
98. Bloom CI, Cabrera C, Arnetorp S, et al. Asthma-related health outcomes associated with short-acting β2-agonist inhaler use: an observational UK study as part of the SABINA global program. Adv Ther. 2020 Oct;37(10):4190-208.Full text Abstract
99. Amin S, Soliman M, McIvor A, et al. Usage patterns of short-acting β2-agonists and inhaled corticosteroids in asthma: a targeted literature review. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2556-64. Abstract
100. Scottish Intercollegiate Guidelines Network (SIGN). Pharmacological management of asthma. Evidence table 4.4a: inhaled corticosteroid vs theophylline. Jul 2019 [internet publication].Full text
101. Scottish Intercollegiate Guidelines Network (SIGN). Pharmacological management of asthma. Evidence table 4.4c: inhaled corticosteroid vs leukotriene receptor antagonists. Jul 2019 [internet publication].Full text
102. Adams NP, Bestall JC, Lasserson TJ, et al. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD003135.Full text Abstract
103. Calpin C, Macarthur C, Stephens D, et al. Effectiveness of prophylactic inhaled steroids in childhood asthma: a systemic review of the literature. J Allergy Clin Immunol. 1997 Oct;100(4):452-7. Abstract
104. Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020 Apr;55(4):1901872.Full text Abstract
105. Stanford RH, Shah MB, D'Souza AO, et al. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012 Dec;109(6):403-7. Abstract
106. Chauhan BF, Jeyaraman MM, Singh Mann A, et al. Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma. Cochrane Database Syst Rev. 2017 Mar 16;3(3):CD010347.Full text Abstract
107. Rodrigo GJ, Castro-Rodríguez JA. Safety of long-acting β agonists for the treatment of asthma: clearing the air. Thorax. 2012 Apr;67(4):342-9.Full text Abstract
108. Currie GP, Small I, Douglas G. Long acting β2 agonists in adult asthma. BMJ. 2013 Aug 6;347:f4662. Abstract
109. Janjua S, Schmidt S, Ferrer M, et al. Inhaled steroids with and without regular formoterol for asthma: serious adverse events. Cochrane Database Syst Rev. 2019 Sep 25;(9):CD006924.Full text Abstract
110. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011 Jan;139(1):28-35. Abstract
111. Bardelas J, Figliomeni M, Kianifard F, et al. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma. 2012 Mar;49(2):144-52. Abstract
112. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011 May 3;154(9):573-82.Full text Abstract
113. Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess. 2013 Nov;17(52):1-342.Full text Abstract
114. Hambly N, Nair P. Monoclonal antibodies for the treatment of refractory asthma. Curr Opin Pulm Med. 2014 Jan;20(1):87-94. Abstract
115. National Institute for Health and Care Excellence. Omalizumab for treating severe persistent allergic asthma. Apr 2013 [internet publication].Full text
116. National Institute for Health and Care Excellence. Mepolizumab for treating severe eosinophilic asthma. Feb 2021 [internet publication].Full text
117. National Institute for Health and Care Excellence. Reslizumab for treating severe eosinophilic asthma. Oct 2017 [internet publication].Full text
118. Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013 Nov;132(5):1086-96. Abstract
119. National Institute for Health and Care Excellence. Benralizumab for treating severe eosinophilic asthma. Mar 2019 [internet publication].Full text
120. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66.Full text Abstract
121. National Institute for Health and Care Excellence. Dupilumab for treating severe asthma with type 2 inflammation. Dec 2021 [internet publication].Full text
122. National Institute for Health and Care Excellence. Tezepelumab for treating severe asthma. Apr 2023 [internet publication].Full text
123. Menzies-Gow A, Wechsler ME, Brightling CE, et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023 May;11(5):425-38. Abstract
124. Asthma and Lung UK. Biologic therapies for severe asthma. Dec 2021 [internet publication].Full text
125. National Institute for Health and Care Excellence. Bronchial thermoplasty for severe asthma. Dec 2018 [internet publication].Full text
126. Torrego A, Solà I, Munoz AM, et al. Bronchial thermoplasty for moderate or severe persistent asthma in adults. Cochrane Database Syst Rev. 2014 Mar 3;(3):CD009910.Full text Abstract
127. Zhou JP, Feng Y, Wang Q, et al. Long-term efficacy and safety of bronchial thermoplasty in patients with moderate-to-severe persistent asthma: a systemic review and meta-analysis. J Asthma. 2016;53(1):94-100. Abstract
128. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Sep 22;365(12):1088-98.Full text Abstract
129. Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug;70(8):748-56.Full text Abstract
130. Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 Oct;4(10):781-96. Abstract
131. Korenblat P, Sher E, Berman G, et al. P069 effect of lebrikizumab on lung function in patients with severe eosinophilic asthma. Ann Allergy Asthma Immunol. 2021 Nov 1;127(5):S34.Full text
132. Szefler SJ, Roberts G, Rubin AS, et al. Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS). Clin Transl Allergy. 2022 Jul;12(7):e12176.Full text Abstract
133. Chan R, Stewart K, Misirovs R, et al. Targeting downstream type 2 cytokines or upstream epithelial alarmins for severe asthma. J Allergy Clin Immunol Pract. 2022 Jun;10(6):1497-505.Full text Abstract
134. Kosloski MP, Kalliolias GD, Xu CR, et al. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials. Clin Transl Sci. 2022 Feb;15(2):384-95.Full text Abstract
135. Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med. 2021 Oct 28;385(18):1656-68.Full text Abstract
136. Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021 Nov;9(11):1288-98. Abstract
137. Sears MR, Greene JM, Willan AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med. 2003 Oct 9;349(15):1414-22.Full text Abstract
138. Phelan PD, Robertson CF, Olinksy A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol. 2002 Feb;109(2):189-94. Abstract
139. James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med. 2005 Jan 15;171(2):109-14.Full text Abstract
140. James AL, Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur Respir J. 2007 Jul;30(1):134-55.Full text Abstract
141. Bai TR, Vonk JM, Postma DS, et al. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007 Sep;30(3):452-6.Full text Abstract
142. Tupper OD, Andersen ZJ, Ulrik CS. Demographic, lifestyle and comorbid risk factors for all-cause mortality in a Danish cohort of middle-aged adults with incident asthma. BMJ Open. 2021 Oct 4;11(10):e049243.Full text Abstract
143. Lommatzsch M, Buhl R, Canonica GW, et al. Pioneering a paradigm shift in asthma management: remission as a treatment goal. Lancet Respir Med. 2024 Feb;12(2):96-9. Abstract
144. Blaiss M, Oppenheimer J, Corbett M, et al. Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment. Ann Allergy Asthma Immunol. 2023 Dec;131(6):782-5.
145. Slade DJ, Kraft M. Airway remodeling from bench to bedside: current perspectives. Clin Chest Med. 2006 Mar;27(1):71-85. Abstract
146. Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2005 Nov;116(5):970-5. Abstract
147. Ring N, Malcolm C, Wyke S, et al. Promoting the use of personal asthma action plans: a systematic review. Prim Care Respir J. 2007 Oct;16(5):271-83.Full text Abstract
148. Riley IL, Jackson B, Crabtree D, et al. A scoping review of international barriers to asthma medication adherence mapped to the theoretical domains framework. J Allergy Clin Immunol Pract. 2021 Jan;9(1):410-8.e4. Abstract
149. van de Hei SJ, Dierick BJH, Aarts JEP, et al. Personalized medication adherence management in asthma and chronic obstructive pulmonary disease: a review of effective interventions and development of a practical adherence toolkit. J Allergy Clin Immunol Pract. 2021 Nov;9(11):3979-94.Full text Abstract
150. Murphy J, McSharry J, Hynes L, et al. Prevalence and predictors of adherence to inhaled corticosteroids in young adults (15-30 years) with asthma: a systematic review and meta-analysis. J Asthma. 2021 May;58(5):683-705. Abstract
151. Chongmelaxme B, Lee S, Dhippayom T, et al. The effects of telemedicine on asthma control and patients' quality of life in adults: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2019 Jan;7(1):199-216. Abstract
152. Jeminiwa R, Hohmann L, Qian J, et al. Impact of eHealth on medication adherence among patients with asthma: a systematic review and meta-analysis. Respir Med. 2019 Mar;149:59-68.Full text Abstract
153. Unni E, Gabriel S, Ariely R. A review of the use and effectiveness of digital health technologies in patients with asthma. Ann Allergy Asthma Immunol. 2018 Dec;121(6):680-91.Full text Abstract
154. Mes MA, Katzer CB, Chan AHY, et al. Pharmacists and medication adherence in asthma: a systematic review and meta-analysis. Eur Respir J. 2018 Aug 23;52(2):1800485.Full text Abstract
155. Jia X, Zhou S, Luo D, et al. Effect of pharmacist-led interventions on medication adherence and inhalation technique in adult patients with asthma or COPD: a systematic review and meta-analysis. J Clin Pharm Ther. 2020 Oct;45(5):904-17.Full text Abstract
156. Ten Have P, van Hal P, Wichers I, et al. Turning green: the impact of changing to more eco-friendly respiratory healthcare - a carbon and cost analysis of Dutch prescription data. BMJ Open. 2022 Jun 14;12(6):e055546.Full text Abstract
157. Peters U, Dixon AE, Forno E. Obesity and asthma. J Allergy Clin Immunol. 2018 Apr;141(4):1169-79.Full text Abstract
158. FitzGerald JM, Gibson PG. Asthma exacerbations. 4: prevention. Thorax. 2006 Nov;61(11):992-9.Full text Abstract
159. UK Health Security Agency. Complete routine immunisation schedule. Oct 2023 [internet publication].Full text
160. UK Health Security Agency. Influenza: The Green Book, chapter 19. Sep 2022 [internet publication].Full text
161. Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD000364.Full text Abstract
162. UK Health Security Agency. COVID-19: The Green Book, chapter 14a. Apr 2023 [internet publication].Full text
Use of this content is subject to our disclaimer